3 yr study of FDA Adverse Event Reporting on anifrolumab shows following AEs- URIs, herpes zoster, infusion reactions, and potential new risks like dyspnea and pyrexia, not in the label. https://t.co/vP2YWGT2vR https://t.co/BruGBtXEBu
Links:
Post-marketing safety signals of anifrolumab in systemic lupus erythematosus: a…
https://buff.ly/vgJoe8I
11-09-2025
